Abstract: The variable-speed accelerator includes an electric device, a transmission device, and a power supply portion that supplies electric power of a constant rated frequency supplied from a power supply to the electric device when the electric device is started. The electric device includes a constant-speed electric motor that rotates a constant-speed input shaft of the transmission device, and a variable-speed electric motor that functions as a generator in a generator mode and also functions as an electric motor in an electric motor mode. When starting the electric device, the power supply portion supplies the electric power generated by the variable-speed electric motor in the generator mode to the constant-speed electric motor after supplying starting power to the constant-speed electric motor and the variable-speed electric motor.

Abstract: A composition, which can prepare hypochlorous acid water having a pH of 5 to 7.5, a concentration of hypochlorous acid of 50 to 500 ppm, a concentration of free chlorine molecules lower than an effective chlorine concentration, the concentration of free chlorine molecules of 20 ppm or less, and a nonionized hypochlorous acid as an active ingredient when diluted with an aqueous vehicle, the composition comprising: 1) one or more selected from trichloroisocyanuric acid, dichloroisocyanuric acid and salts thereof; and 2) a buffer salt (provided that, a chlorite of an alkali metal or alkaline earth metal is included in neither the aqueous medium nor the composition).

Abstract: An anti-Acanthamoeba agent contains luliconazole crystal as an active ingredient. The luliconazole has a crystal habit in which a ratio of I (20-2) to a total sum of I (001), I (100), I (10-1), I (011), I (110), I (11-1), I (10-2), I (11-2), I (020), I (021), I (20-2), I (121), I (013), I (11-3), and I (221) is 12% or more and/or a ratio of I (10-2) to a total sum of I (001), I (100), I (10-1), I (011), I (110), I (11-1), I (10-2), I (11-2), I (020), I (021), I (20-2), I (121), I (013), I (11-3), and I (221) is 20% or more.

Abstract: An object of the present invention is to provide a novel anti-Tritrichomonas agent. Provided is an anti-Tritrichomonas agent containing luliconazole.

Abstract: Means for improving the solubility of luliconazole is provided. A crystal of luliconazole represented by the following formula is provided, wherein the crystal has such a crystal habit that (011) plane is a specific crystal growth plane. The crystal is characterized in that I(011) with respect to a sum total of I(001), I(100), I(10-1), I(011), I(110), I(11-1), I(10-2), I(11-2), I(020), I(021), I(20-2), I(121), I(013), I(11-3), and I(221) is not less than 25%, provided that integrated intensities of diffraction peaks, which correspond to the (001), (100), (10-1), (011), (110), (11-1), (10-2), (11-2), (020), (021), (20-2), (121), (013), (11-3), and (221) planes, are designated as I(001), I(100), I(10-1), I(011), I(110), I(11-1), I(10-2), I(11-2), I(020), I(021), I(20-2), I(121), I(013), I(11-3), and I(221) respectively in relation to the diffraction peaks detected in a range of 2?=5 to 35° in a powder X-ray diffractometry using CuK? radiation.

Abstract: Means for improving the solubility of luliconazole is provided. A crystal of luliconazole represented by the following formula is provided, wherein the crystal has such a crystal habit that (011) plane is a specific crystal growth plane. The crystal is characterized in that I(011) with respect to a sum total of I(001), I(100), I(10-1), I(011), I(110), I(11-1), I(10-2), I(11-2), I(020), I(021), I(20-2), I(121), I(013), I(11-3), and I(221) is not less than 25%, provided that integrated intensities of diffraction peaks, which correspond to the (001), (100), (10-1), (011), (110), (11-1), (10-2), (11-2), (020), (021), (20-2), (121), (013), (11-3), and (221) planes, are designated as I(001), I(100), I(10-1), I(011), I(110), I(11-1), I(10-2), I(11-2), I(020), I(021), I(20-2), I(121), I(013), I(11-3), and I(221) respectively in relation to the diffraction peaks detected in a range of 2?=5 to 35° in a powder X-ray diffractometry using CuK? radiation.

Abstract: An object is to provide means for precisely treating pneumonia caused by intracellular parasite, protozoa, and/or fungus. A pharmaceutical composition for pneumonia, comprising a compound represented by the following general formula (1) as an active ingredient: (In the formula, R represents a halogen atom or a hydrogen atom, and X represents a halogen atom.

Abstract: An object is to provide means for precisely treating vaginitis caused by intracellular parasite, protozoa, and/or fungus. A pharmaceutical composition for vaginitis, comprising a compound represented by the following general formula (1) as an active ingredient: (1) (In the formula, R represents a halogen atom or a hydrogen atom, and X represents a halogen atom.

Abstract: An object is to provide means for improving the solubility of luliconazole. Disclosed is a crystal consisting of luliconazole and short chain alcohol having a number of carbon atom or atoms of 1 to 4.

Abstract: An object is to provide means for improving the solubility of luliconazole. Disclosed is a crystal consisting of luliconazole and short chain alcohol having a number of carbon atom or atoms of 1 to 4.

Abstract: Dibenzosuberanyl piperazine derivatives represented by the following formula (I): wherein R represents an aliphatic hydrocarbon group, which may contain one or more heteroatom-containing substituent groups and may preferably contain 2 to 30 carbon atoms, and physiologically acceptable salts thereof; and medicinal compositions containing these dibenzosuberanyl piperazine derivatives and/or physiologically acceptable salts thereof. These compounds show effectiveness in allowing resistance-acquired causes of diseases to restore sensitivity to drug, that is, a resistance overcoming effect.

Abstract: Dibenzosuberanyl piperazine derivatives represented by the following formula (I): 1

Abstract: A diphenylpiperazine derivative represented by general formula (1), salt thereof, and drug for the circulatory organs containing the same as the active ingredient: ##STR1## wherein R.sup.1 and R.sup.2 may be the same or different from each other and each represents hydrogen, halogen, alkyl, alkoxy, nitro, amino, hydroxy, optionally esterified carboxyl or trifluoromethyl; R.sup.3 represents hydrogen, alkyl, aralkyl, acyl, nitro or optionally esterified carboxymethyl; Ar represents phenyl or naphthyl which may have one to three substituents such as halogen, alkyl, alkoxy, aryloxy, aralkyloxy, nitro, amino, cyano, acyl, hydroxy, optionally esterified carboxyl, substituted sulfonyl, aryl or trifluoromethyl; Z represents sulfur or -NR.sup.4 - wherein R.sup.4 represents hydrogen, alkyl, aralkyl, acyl, aryl, substituted sulfonyl or optionally esterified carboxyl; m represents a number of 1 to 5; and n represents a number of 0 to 5.

Abstract: Disclosed herein is an antiprotozoal composition containing a 2-nitroimidazole derivative as its active component. This drug is especially useful against Trypanosoma cruzi. Process for the preparation is also disclosed.

Abstract: The present invention relates to a 2-nitroimidazole derivative represented by the following general formula (I): ##STR1## wherein R.sub.1, R.sub.2 and R.sub.3 may be the same or different from each other and mean individually a hydrogen atom or an acyl group, and a radiosensitizer containing the same. The compound (I) according to this invention has an excellent radiosensitizing effect and high safety, so that a radiosensitizer containing the same is remarkably useful in the radiotherapy of cancers.

Abstract: A novel heterocyclic derivative of formula (I): ##STR1## wherein R.sub.1 represents ##STR2## and R.sub.2 represents hydrogen or acyl. When R.sub.2 is acyl, the derivative can be prepared, for example, by the following process: ##STR3## wherein R.sub.4 is acyl and R.sub.1 is ##STR4## The derivative is less toxic and has radiosensitizing activity and antiviral activity even at a low concentration.Radiosensitizing agents and antiviral agents containing the derivative as active component are also disclosed.

Abstract: A novel heterocyclic derivative of formula (I): ##STR1## wherein R.sub.1 represents ##STR2## and R.sub.2 represents hydrogen or acyl. When R.sub.2 is acyl, the derivative can be prepared, for example, by the following process: ##STR3## wherein R.sub.4 is acyl and R.sub.1 is ##STR4## The derivative is less toxic and has radiosensitizing activity and antiviral activity even at a low concentration.Radiosensitizing agents and antiviral agents containing the derivative as active component are also disclosed.